Because GLP-1 related medicines can affect appetite and stomach emptying, a clinician should know about gastrointestinal disease, prior pancreatitis, gallbladder problems, kidney issues, planned surgery, pregnancy, breastfeeding, and diabetes medicines
BPC-157 is investigational, not FDA-approved, and banned by WADA
Do not make changes to your treatment without their guidance, as this may affect glycaemic control or weight management outcomes
Companies get around this by labeling it as a "research chemical not for human consumption." This means the product is completely unregulated, and you have no way of knowing if it's pure, sterile, or even contains the correct substance
Dietary modifications reduce nausea substantially